Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited Janssen, the company manufacturing abiraterone acetate (AA; tradename Zytiga(®)), to submit evidence for the clinical and cost effectiveness of AA in combination with prednisone/prednisolone (AAP) compared with watchful waiting (i....

Descripción completa

Detalles Bibliográficos
Autores principales: Ramaekers, Bram L. T., Riemsma, Rob, Tomini, Florian, van Asselt, Thea, Deshpande, Sohan, Duffy, Steven, Armstrong, Nigel, Severens, Johan L., Kleijnen, Jos, Joore, Manuela A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253156/
https://www.ncbi.nlm.nih.gov/pubmed/27566699
http://dx.doi.org/10.1007/s40273-016-0445-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253156/
https://www.ncbi.nlm.nih.gov/pubmed/27566699
http://dx.doi.org/10.1007/s40273-016-0445-5

Ejemplares similares